Answers are grounded in this paper and cite their sources.
Aromatase inhibitors (AIs) have transformed the treatment of hormone receptor-positive breast cancer by suppressing estrogen biosynthesis. However, aromatase and estrogen signaling have also been implicated in several malignancies traditionally classified as non-hormone-dependent, where their effects on tumor progression, metabolism, and antitumor immunity appear to depend on tumor type, receptor context, and the tumor microenvironment. This emerging evidence has generated increasing interest in repurposing AIs beyond their conventional endocrine indications. In this review, we summarize the molecular mechanisms linking aromatase and estrogen signaling to oncogenic pathways, tumor metabolism, and modulation of the tumor microenvironment in non-hormone-dependent malignancies. We further discuss preclinical studies demonstrating that AIs not only inhibit intratumoral estrogen production but also enhance the efficacy of chemotherapy and immune checkpoint inhibitors by suppressing pro-survival signaling, reducing PD-L1 expression, reshaping lipid metabolism, and restoring antitumor immune responses. Finally, we critically examine the currently available clinical studies, highlighting both the encouraging biological rationale and the limitations of existing early-phase trials. Overall, aromatase can be considered a broad regulator of cancer biology. Addressing three major challenges - accurate patient stratification, precise identification of predictive biomarkers and design of prospective clinical trials -will be essential to realize the translational potential of AIs and determine whether they can enhance current anticancer treatments.
No takes yet. Share an insight, caveat, or question.
Meoli et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: